Abstract

The majority of proteins in mammalian cells are modified by covalent attachment of an acetyl-group to the N-terminus (Nt-acetylation). Paradoxically, Nt-acetylation has been suggested to inhibit as well as to promote substrate degradation. Contrasting these findings, proteome-wide stability measurements failed to detect any correlation between Nt-acetylation status and protein stability. Accordingly, by analysis of protein stability datasets, we found that predicted Nt-acetylation positively correlates with protein stability in case of GFP, but this correlation does not hold for the entire proteome. To further resolve this conundrum, we systematically changed the Nt-acetylation and ubiquitination status of model substrates and assessed their stability. For wild-type Bcl-B, which is heavily modified by proteasome-targeting lysine ubiquitination, Nt-acetylation did not correlate with protein stability. For a lysine-less Bcl-B mutant, however, Nt-acetylation correlated with increased protein stability, likely due to prohibition of ubiquitin conjugation to the acetylated N-terminus. In case of GFP, Nt-acetylation correlated with increased protein stability, as predicted, but our data suggest that Nt-acetylation does not affect GFP ubiquitination. Similarly, in case of the naturally lysine-less protein p16, Nt-acetylation correlated with protein stability, regardless of ubiquitination on its N-terminus or on an introduced lysine residue. A direct effect of Nt-acetylation on p16 stability was supported by studies in NatB-deficient cells. Together, our studies argue that Nt-acetylation can stabilize proteins in human cells in a substrate-specific manner, by competition with N-terminal ubiquitination, but also by other mechanisms that are independent of protein ubiquitination status.

Details

Title
N-terminal acetylation can stabilize proteins independent of their ubiquitination
Author
van de Kooij, Bert 1 ; de Vries, Evert 2 ; Rooswinkel, Rogier W. 3 ; Janssen, George M. C. 4 ; Kok, Frédérique K. 5 ; van Veelen, Peter A. 4 ; Borst, Jannie 2 

 Leiden University Medical Center, Department of Human Genetics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598) 
 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Leiden University Medical Center, Department of Immunology and Oncode Institute, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393) 
 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Leiden Academic Centre for Drug Research, Leiden, the Netherlands (GRID:grid.5132.5) (ISNI:0000 0001 2312 1970) 
Pages
5333
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2793847162
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.